إسرائيل - العربية - Ministry of Health

abic ltd. - ofloxacin 200 mg - tablets - ofloxacin - bacterial infections due to ofloxacin-susceptible microorganisms, such as:- acute, chronic, or recurrent lower respiratory tract infections (bronchitis) pneumonia (not for the treatment of first choice in pnemonia caused by pneumococci). - chronic and recurrent infections of the ear, nose, and throat. ofloxacin is in general not indicated for the treatment of acute tonsillitis caused by betahaemolytic streptococci. - infections of soft tissues and skin. - infections of the bones and joints. - abdominal infections including infections in the pelvis minor and bacterial enteritis. - infections of the kidney, urinary tract, and genital organs, gonorrhoea.prevention of infections due to ofloxacin-susceptible pathogens in patients with a significant reduction in resistance to infections (e.g. in neutropenic state).

إسرائيل - العربية - Ministry of Health

dexcel ltd - ofloxacin 200 mg - caplets - ofloxacin - bacterial infections due to ofloxacin-susceptible microorganisms, such as: upper and lower urinary tract infections, lower respiratory tract infections uncomplicated urethral and cervical gonorrhoea, non-gonococcal urethritis and cervicitis, skin and soft tissue infections.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - bicalutamide 50 mg - tablets - bicalutamide - for the treatment of advanced prostate cancer in combination with lhrh analog therapy or surgical castration.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - bicalutamide 150 mg - tablets - bicalutamide - in patients with locally advanced prostate cancer (t3-t4 any n m0 t1-t2 n+ m0) bicalutamide is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - anastrozole 1 mg - tablets - anastrozole - treatment of advanced breast cancer in post menopausal women. efficay has not been demonstrated in estrogen receptor negative patients unless they had a previous positive clinical response to tamoxifen. adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer. adjuvant treatment of early breast cancer in hormone receptor positive postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

إسرائيل - العربية - Ministry of Health

abic ltd. - diclofenac sodium 50 mg - suppositories - diclofenac - rheumatoid arthritis, osteoarthritis, low back pain and other acute musculoskeletal .disorders such as periarthritis, tendinitis, tenosynovitis, bursitis, sprains, strains and dislocation, ankylosing spondylitis and acute gout.control of pain and inflammation in orthopedic, dental, and other monor surgery.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - paracetamol 250 mg / 5 ml - syrup - paracetamol - analgesic, antipyretic.

إسرائيل - العربية - Ministry of Health

j-c health care ltd - loperamide hydrochloride 2 mg - capsules - antipropulsives - control and symptomatic relief of acute diarrhea.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - chlorpheniramine maleate 2 mg - tablets - substituted alkylamines - symptomatic relief of perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis, mild uncomplicated urticaria and angioedema, amelioration of allergic reactions to blood or plasma, dermatographism, adjunctive therapy in anaplylactic reactions.

إسرائيل - العربية - Ministry of Health

sanofi - aventis israel ltd - ramipril 2.5 mg - tablets - ace inhibitors, plain - hypertension congestive heart failure reduction of mortality in patients after mi with left ventricular dysfunction. for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.